

MGUS / SMM

1. NCT04776395: Phase 2: Iberdomide Alone or in Combination with Dex for Intermediate/High-Risk SMM

R Emory University	Iberdomide Dex	Phase 2 NCT04776395	First Posted: 2021	Bristol-Myers Squibb
------------------------------	-------------------	------------------------	-----------------------	----------------------

2. The PCROWD Study invites people with precursor conditions to Share samples a few times each year

R -DFCI -PCROWD Stud	Non-Invasive Liquid Biopsy			
-----------------------------------	----------------------------	--	--	--

3. IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test

R -DFCI -Impact study	Blood test		First Posted: 2020	
------------------------------------	------------	--	-----------------------	--

4. NCT04920084: A Study of a Plant-Based Diet in People with MGUS / Smoldering Myeloma - NUTRIVENTION

R -Memorial Sloan Kettering Cancer Center -NUTRIVENTION	Plant-Based Diet	Phase 2 NCT04920084	First Posted: 2020	
--	------------------	------------------------	-----------------------	--

5. NCT04270409: Phase 3 - Isatuximab in Combination with Lenalidomide and Dex High-risk SMM (ITHACA)

R ITHACA	Isatuximab Lenalidomide Dexamethasone	Phase 3 NCT04270409	First Posted: 2020	Sanofi
--------------------	---	------------------------	-----------------------	--------

6. The clonoSEQ® Watch Registry

R Adaptive Biotechnologies	clonoSEQ Assay	NCT04545333	First Posted: 2020	Adaptive Biotechnologies
--------------------------------------	----------------	-------------	-----------------------	--------------------------

7. <u>NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patient</u>				
R University of Chicago MRD2STOP	Screening	Phase 2 NCT04108624	First Posted: 2019	
8. <u>NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM</u>				
R -Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group) -National Cancer Institute (NCI) -DETER-SMM -EAA173	Lenalidomide, Dex +/- Daratumumab	Phase 3 NCT03937635	First Posted: 2019	
9. <u>NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants with Smoldering MM</u>				
R M.D. Anderson Cancer Center	Personalized Vaccine	Phase 1 NCT03631043	First Posted: 2018	
10. <u>NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population</u>				
R -DFCI -Stand Up To Cancer -PROMISE Study	Sample of Blood	NCT03689595	First Posted: 2018	
11. <u>NCT03657251: MMRF CureCloud Research Initiative</u>				
R Multiple Myeloma Research Foundation	Genetic: liquid biopsy	NCT03657251	First Posted: 2018	

12. <u>NCT03289299: Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT</u>				
R -International Myeloma Foundation -ASCENT	Carfilzomib Lenalidomide Daratumumab Dexamethasone	Phase 2 NCT03289299	First Posted: 2017	Amgen Janssen Celgene Trevie, Inc
13. <u>NCT03327597: Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)</u>				
-International Myeloma Foundation/Black Swan Research Initiative -University of Iceland -iStopMM	Clinical follow-up 1	NCT03327597	First Posted: 2017	
14. <u>NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM</u>				
R -Massachusetts General Hospital	Lenalidomide PVX-410 Citarinostat	Phase 1 NCT02886065	First Posted: 2016	Celgene, OncoPep, Inc
15. <u>NCT02960555: Phase 2 - Isatuximab in Patients with High-Risk Smoldering Plasma Cell Myeloma</u>				
R -M.D. Anderson Cancer Center -National Cancer Institute (NCI)	Isatuximab	Phase 2 NCT02960555	First Posted: 2016	
16. <u>NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High-Risk Smoldering MM GEM-CESAR trial</u>				
-PETHEMA/GEM -GEM-CESAR	Carfilzomib, Lenalidomide, Melphalan, Dex	Phase 2 NCT02415413	First Posted: 2015	
17. <u>NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS</u>				
-CENTAURUS	Daratumumab	Phase 2 NCT02316106	First Posted: 2014	Janssen

18. <u>NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma</u>				
National Cancer Institute (NCI)	Carfilzomib, Lenalidomide, Dex	Phase 2 NCT01572480	First Posted 2012	
19. <u>NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06</u>				
-National Cancer Institute (NCI) -ECOG - E3A06	Lenalidomide	Phase 3 NCT01169337	First Posted: 2010	
20. <u>NCT00480363: Phase 3: Revlimid / Dex (ReDex) VS Observation in Smoldering MM (QUIREDEX)</u>				
-PETHEMA/GEM -QUIREDEX	Lenalidomide, Dex VS Observation	Phase 3 NCT00480363	First Posted: 2007	Celgene